In a study, Guo et al. [82] prepared novel CD44-targeted liposomal NCs loaded with anti-IL6R antibodies, which have the capacity to selectively target TME of CD44+ breast cancer cells in luminal and triple-negative breast cancer (TNBC) mouse models. This evidence concerns the gene CD44 and triple-negative breast carcinoma.